Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.961
Peer-review started: August 11, 2015
First decision: September 29, 2015
Revised: September 30, 2015
Accepted: November 19, 2015
Article in press: November 19, 2015
Published online: January 21, 2016
Processing time: 157 Days and 1.9 Hours
Inflammatory bowel disease (IBD) is associated with increased risk of colorectal cancer (CRC). The risk is known to increase with longer duration of the disease, family history of CRC, and history of primary sclerosing cholangitis. The diagnosis of the neoplastic changes associated with IBD is difficult owing to the heterogeneous endoscopic appearance and inter-observer variability of the pathological diagnosis. Screening and surveillance guidelines have been established which aim for early detection of neoplasia. Several surgical options are available for the treatment of IBD-associated neoplasia. Patients’ morbidities, risk factors for CRC, degree and the extent of neoplasia must be considered in choosing the surgical treatment. A multidisciplinary team including the surgeon, gastroenterologist, pathologist, and the patient who has a clear understanding of the nature of their disease is needed to optimize outcomes.
Core tip: This review summarizes the natural history of inflammatory bowel disease associated dysplasia and colorectal cancer. An up to date review of risk factors for inflammatory bowel disease associated colorectal cancer is included. Highlights include surgeon specific factors to aid in joint decision making with the patient regarding further management of their disease. These factors include the management options of continued appropriate endoscopic surveillance and the different disease specific surgical options. Finally, it summarizes the long-term surveillance program and the long-term prognosis following surgery for inflammatory bowel disease associated neoplasia.